{"id":8569,"date":"2024-05-30T10:34:18","date_gmt":"2024-05-30T02:34:18","guid":{"rendered":"https:\/\/clinicalvalue.com\/?p=8569"},"modified":"2024-05-30T11:46:50","modified_gmt":"2024-05-30T03:46:50","slug":"research-spotlight","status":"publish","type":"post","link":"https:\/\/clinicalvalue.com\/en-au\/research-spotlight\/","title":{"rendered":"Research Spotlight"},"content":{"rendered":"<p>[vc_row][vc_column][vc_column_text]<\/p>\n<h2>Hepatocellular carcinoma surveillance and the emerging role of biomarker-based models<\/h2>\n<p>In the latest Research Review Educational Series, Associate Professor Simone Strasser, a senior staff specialist at Royal Prince Alfred Hospital, Sydney, explores <a href=\"https:\/\/www.researchreview.com.au\/au\/Clinical-Area\/Internal-Medicine\/Medical-Oncology\/Liver-Cancer\/Educational-Series-%e2%80%93-Hepatocellular-carcinoma-surv.aspx?hash=70e5552165831516d6465aec27f9f8f3d0249420643d6b7ff3a3d85fe4ff2347\" target=\"_blank\" rel=\"noopener\">hepatocellular carcinoma (HCC) surveillance and the emerging role of biomarker-based models<\/a>.<\/p>\n<p>Strasser notes that <em>\u201cit was presumed that with widespread uptake of neonatal and childhood hepatitis B vaccination, effective hepatitis B antiviral therapy, and high uptakes of hepatitis C curative therapies, rates of HCC would start to decline in the community\u201d<\/em>.<\/p>\n<p>However, this has not happened, due to an increase in population rates of obesity-related metabolic-associated fatty liver disease (MAFLD). This places increasing emphasis on the prevention and management of obesity and metabolic dysfunction in our battle against HCC.<\/p>\n<p>To learn more about the emerging challenges in this area you can read the full article <a href=\"https:\/\/www.researchreview.com.au\/au\/Clinical-Area\/Internal-Medicine\/Medical-Oncology\/Liver-Cancer\/Educational-Series-%e2%80%93-Hepatocellular-carcinoma-surv.aspx?hash=70e5552165831516d6465aec27f9f8f3d0249420643d6b7ff3a3d85fe4ff2347\" target=\"_blank\" rel=\"noopener\">here<\/a>.[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p>\n<h2>Further information<\/h2>\n<p>You can explore the latest advances in hepatocellular carcinoma through our curated list of recent publications.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text] Hepatocellular carcinoma surveillance and the emerging role of biomarker-based models In the latest Research Review Educational Series, Associate Professor Simone Strasser, a senior staff specialist at Royal Prince Alfred Hospital, Sydney, explores hepatocellular carcinoma (HCC) surveillance and the emerging role of biomarker-based models. Strasser notes that \u201cit was presumed that with widespread uptake of neonatal and childhood hepatitis B&#8230;<\/p>\n","protected":false},"author":19,"featured_media":8579,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1284],"tags":[1407,1301,1406,1405],"cancer-type":[1296],"country":[1268],"class_list":["post-8569","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-disease-awareness-en-au","tag-clinical-insights","tag-hcc-en-au","tag-research-spotlight","tag-spotlight","cancer-type-liver-en-au","country-au"],"jetpack_featured_media_url":"https:\/\/clinicalvalue.com\/app\/uploads\/2024\/05\/Roche_114371.png","_links":{"self":[{"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/posts\/8569"}],"collection":[{"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/comments?post=8569"}],"version-history":[{"count":3,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/posts\/8569\/revisions"}],"predecessor-version":[{"id":8581,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/posts\/8569\/revisions\/8581"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/media\/8579"}],"wp:attachment":[{"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/media?parent=8569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/categories?post=8569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/tags?post=8569"},{"taxonomy":"cancer-type","embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/cancer-type?post=8569"},{"taxonomy":"country","embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/country?post=8569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}